No Data
No Data
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Ionis Pharmaceuticals Inc (NASDAQ:IONS) released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (
Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical
14 analysts have shared their evaluations of Ultragenyx Pharmaceutical (NASDAQ:RARE) during the recent three months, expressing a mix of bullish and bearish perspectives.The following table
Express News | Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $115 Price Target
Evercore Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $70
Evercore analyst Liisa Bayko maintains $Ultragenyx Pharmaceutical(RARE.US)$ with a buy rating, and adjusts the target price from $80 to $70.According to TipRanks data, the analyst has a success rate
Press Release: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NOVATO, Calif., July 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company
A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $45 to $135
On Jul 19, major Wall Street analysts update their ratings for $Ultragenyx Pharmaceutical(RARE.US)$, with price targets ranging from $45 to $135.Evercore analyst Liisa Bayko maintains with a buy